(ED NOTE: This is an important, significant study, since it provides an option to a very common procedure, the biopsy.  Also, it would be less invasive for the patient)


March 8, 2014

Join us for an online seminar on March 13 at 10:00 AM EDT, sponsored by Transgenomic.

Register here now!

This online seminar shares examples of a study being carried out by Transgenomic and MD Anderson that demonstrates the benefits of using circulating free DNA as a surrogate for formalin-fixed, paraffin-embedded tumor tissue. We will demonstrate how combining a PCR technique known as ICP with the analysis of cfDNA can dramatically improve the detection, treatment, and monitoring of cancer patients in the future and potentially replace tissue biopsies. 

While circulating cell-free DNA (cfDNA) has been known for more than 60 years, the use of cfDNA as a molecular diagnostic tool — or so-called “blood biopsy” — has only recently been exploited for use in cancer treatment and monitoring. cfDNA provides a unique window into a cancer patient’s molecular landscape, which, unlike the static sampling of DNA from an FFPE tumor, is dynamic. The dynamic nature of cfDNA provides real time mutational analysis of primary and metastatic tumors for determining treatment options for patients as well as for the monitoring of treatment effectiveness and disease reoccurrence. However, the challenge for this analysis is the low concentration of cfDNA found in a patient’s plasma or serum and the potentially low level of mutations in this low concentration of cfDNA. 

Transgenomic has developed and optimized the technique known as ICP (Improved and Complete Enrichment COamplification at Lower Denaturation PCR) for enriched amplification of mutant DNA. The enrichment is due to the differences in denaturation temperatures between mutant DNA duplexes and normal “wild-type” DNA duplexes. Transgenomic believes the pairing of ICP with cfDNA provides oncologists with a tool to detect cancers earlier and more accurately, allowing personalized targeted drug therapy and treatment monitoring, and resulting in the best possible outcome for patients. 

The use of ICP coupled with Sanger sequencing shows greater than 400-fold enrichment for the detection of mutations and is a cost-effective assay when interrogating cfDNA for a small number of mutations. Furthermore, ICP can now be multiplexed prior to mutation characterization on next-generation sequencing platforms. This has the potential to monitor greater than 600 mutations from the same sample of cfDNA. This webinar will demonstrate how cfDNA + ICP + NGS provides the sensitivity required to make the “blood biopsy” the methodology of choice for cancer patient care decisions, monitoring and surveillance.


No comments

Be the first one to leave a comment.

Post a Comment